Eledon Pharmaceuticals, Inc. (FRA:2TK)

Market Cap	105.64M
Revenue (ttm)	n/a
Net Income (ttm)	-70.46M
Shares Out	n/a
EPS (ttm)	-0.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	137
Open	1.220
Previous Close	1.170
Day's Range	1.220 - 1.220
52-Week Range	1.170 - 4.660
Beta	n/a
RSI	33.65
Earnings Date	Nov 20, 2025

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney tran...

• Industry: Biological Products, Except Diagnostic Substances
• CEO: David-Alexandre Gros
• Employees: 31
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 2TK

Financial Performance

Financial numbers in USD